Despite Regulatory Setback, Spectrum Still "Unique Investment Opportunity," Says Analyst
Yesterday, the FDA's Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) poziotinib's (pozi) risk/benefit ratio and concluded that pozi's benefits do not outweigh the risks for the treatment of HER2 exon 20 insertion mutations.
Meanwhile, with a newly approved commercial product Rolvedon launching into the $2.3 billion G-CSF space, JMP Securities believes that Spectrum shares still represent a unique investment opportunity with a 34% potential downside (bear case is $0.42) and 1,003% potential upside (bull case is $7).
JMP reiterates its Market Outperform rating and a price target of $4.
The analyst writes that the four "yes" votes reiterated the need for new therapies in HER2 exon 20 mutations wherein the treatment options are limited.
Additionally, given the well-understood safety profile of TKIs, the four "yes" voters indicated that the side effect profile could be managed well.
Furthermore, JMP acknowledges that given the current cash position, the company would need to make efforts to conserve cash, including cutting R&D, along with a potential capital raise. In a change to the model, JMP has reduced the R&D costs beginning 1Q23 by 30%.
Price Action: SPPI shares are down 33.80% at $0.42 on the last check Friday.
Latest Ratings for SPPI
Date | Firm | Action | From | To |
---|---|---|---|---|
Oct 2020 | HC Wainwright & Co. | Reiterates | Buy | |
Sep 2020 | JMP Securities | Initiates Coverage On | Outperform | |
Aug 2020 | HC Wainwright & Co. | Maintains | Buy |
View More Analyst Ratings for SPPI
View the Latest Analyst Ratings
See more from Benzinga
After Regulatory Setback, Spectrum Pharma Secures Up To $65M In Debt Funding
FDA's Adcomm Gives Thumbs Down To Spectrum Pharmaceuticals' Lung Cancer Candidate
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.